Home \ Neuropediatrics \ Age continuum of ischemic-hypoxic brain lesions. Use of Mexidol for ADHD in children and adults

Age continuum of ischemic-hypoxic lesions of the brain. The use of Mexidol for ADHD in children and adults

The brain in focus of arterial hypertension

Peculiarities of managing elderly patients

The brain is a key target organ for treatment of cerebrovascular risks

Mexidol as a geroprotector: potential and prospects

Neuroprotection in arterial hypertension and cognitive impairment

The Connection Between Vascular Diseases of the Brain and Eye: A Neurologist and Ophthalmologist's Perspective

Ischemic stroke: clinical guidelines and practical aspects

NIHSS and mRS: Gold Standards in Neuroscience

Cognitive impairment caused by arterial hypertension: from clinical guidelines to practical algorithms

The brain is a target organ for arterial hypertension: features of management of the elderly patient

Time codes:

01:55
Causes and manifestations of attention deficiency syndrome
10:00
Development of attention deficiency syndrome
13:51
Attention deficiency syndrome in adults
16:38
Medical and social consequences of attention deficiency syndrome
18:29
Treatment of attention deficiency syndrome
23:36
Improving parental competence
27:52
Attention deficit syndrome with hyperactivity
29:27
Treatment and effectiveness
31:19
Pathogenesis and treatment
41:30
Oxidative stress and its effect on the brain
45:16
Mexidol® and its effect on attention deficit syndrome with hyperactivity
50:12
Clinical research and use of Mexidol

Anatoly Ivanovich Fedin – Doctor of Medical Sciences, Professor Emeritus, Head of the University Clinic of Neurology at the N.I. Pirogov Russian National Research Medical University, Honored Doctor of the Russian Federation

Chutko Leonid Semenovich – Doctor of Medical Sciences, Professor, Head of the Center for Behavioral Neurology at the N.P. Bekhtereva Institute of the Human Brain of the Russian Academy of Sciences

Announcement:

Many adult illnesses begin in childhood. Attention deficit hyperactivity disorder (ADHD) is a disorder characterized by inattention, hyperactivity, and impulsivity and can be caused by various factors, including genetic, perinatal, and psychological factors. Treatment of ADHD in children involves psychological intervention, psychotherapy, and nootropic medications. One such medication with a proven high safety profile is Mexidol®.In clinical trials, Mexidol®demonstrated high efficacy and safety in the treatment of children with attention deficit disorder, resulting in improved cognitive function, antiasthenic effects, and normalization of autonomic functions.

All videos Next video

The brain in focus of arterial hypertension

Peculiarities of managing elderly patients

The brain is a key target organ for treatment of cerebrovascular risks

Mexidol as a geroprotector: potential and prospects

Neuroprotection in arterial hypertension and cognitive impairment

The Connection Between Vascular Diseases of the Brain and Eye: A Neurologist and Ophthalmologist's Perspective

Ischemic stroke: clinical guidelines and practical aspects

NIHSS and mRS: Gold Standards in Neuroscience

Cognitive impairment caused by arterial hypertension: from clinical guidelines to practical algorithms

The brain is a target organ for arterial hypertension: features of management of the elderly patient

Time codes:

01:55
Causes and manifestations of attention deficiency syndrome
10:00
Development of attention deficiency syndrome
13:51
Attention deficiency syndrome in adults
16:38
Medical and social consequences of attention deficiency syndrome
18:29
Treatment of attention deficiency syndrome
23:36
Improving parental competence
27:52
Attention deficit syndrome with hyperactivity
29:27
Treatment and effectiveness
31:19
Pathogenesis and treatment
41:30
Oxidative stress and its effect on the brain
45:16
Mexidol® and its effect on attention deficit syndrome with hyperactivity
50:12
Clinical research and use of Mexidol

Block of articles on this topic

The results of an international multicenter randomized double-blind-controlled study of evaluating the effectiveness of the effectiveness and safety of consistent therapy of patients with chronic brain ischemia with Mexidol and Mexidol Forte 250 (study of Memo)

Registered on ClinicalTrials

A.I. FEDIN¹, V.V. ZAKHAROV², M.M. TANASHYAN³, E.I. CHUKANOVA¹, E.N. MAJIDOVA⁴, L.A. SCHEPANKEVICH^5.6, O.D. OSTROUMOVA⁷

¹Pirogov Russian National Research Medical University, Moscow, Russia;
²I.M. Sechenov First Moscow Medical University,
³Neurology Research Center,
⁴, Russia;
⁵Novosibirsk State Medical University, Novosibirsk
⁶Federal Research Center for Fundamental and Translational Medicine, Novosibirsk, Russia;
⁷Russian Medical Academy of Continuous Professional Education, Moscow, Russia

Place of publication:
S.S. KORSAKOV JOURNAL OF NEUROLOGY AND PSYCHIATRY, 2021, Vol. 121, No. 11

The effectiveness of Mexidol in patients of different age groups with chronic brain ischemia with cognitive disorders (the results of subanalysis of the international multicenter randomized double blind placebo-controlled study of memes)

Authors:
V.V. ZAKHAROV¹, O.N. TKACHEV^2,³, E.A. MKHITARYAN^2,³, A.I. FEDIN²

International multicenteric randomized double-tied placebo-controlled study of evaluating the effectiveness and safety of sequential therapy of patients with chronic brain ischemia drugs Mexidol® and Mexidol® Forte 250 (study of memo): Subanalysis results in patients with arterial hypertension

V.V. ZAKHAROV¹, O.D. OSTROUMOVA^1,2, A.I. KOCHETKOV², M.V. KLEPIKOVA², A.I. FEDIN³

¹Federal State Autonomous Educational Institution of Higher Education “I.M. Sechenov First Moscow State Medical University” of the Russian Ministry of Health (Sechenov University);
²Federal State Budgetary Educational Institution of Higher Professional Education “Russian Medical Academy of Continuous Professional Education” of the Russian Ministry of Health, Moscow;
³Federal State Autonomous Educational Institution of Higher Education “N.I. Pirogov Russian National Research Medical University” of the Russian Ministry of Health, Moscow

Place of publication:
THERAPY No. 1 (63) 2023

To the question of the evidence base of neuroprotective therapy: Focus on ethylmethylhydroxypyridine succinate

Authors:
A.I. KOCHETKOV, N.A. SHATALOVA, M.V. KLEPIKOVA, T.V. FILIPPOVA, O.D. OSTROUMOVA
Federal State Budgetary Educational Institution of Higher Professional Education “Russian Medical Academy of Continuous Professional Education” of the Ministry of Health of the Russian Federation, Moscow

Approaches to pharmacotherapy of vascular moderate cognitive disorders in patients of various age groups

Authors:
V.V. ZAKHAROV¹, A.I. FEDIN², E.A. MKHITARYAN^2,³

THE INFORMATION IS INTENDED FOR HEALTHCARE AND PHARMACEUTICAL PROFESSIONALS. THIS INFORMATION IS NOT INTENDED AS A SUBSTITUTE FOR MEDICAL ADVICE.

Source of photos and images Shutterstock.com